Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Non-Invasive breast scan aims to find the cause of nipple discharge

NCT ID NCT05812040

NEW Diagnosis Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Women with pathological nipple discharge often need surgery to find the cause, but standard mammograms and ultrasounds can miss cancer. Researchers are testing a non-invasive breast scan called high-resolution magnetic resonance ductography (HR-MRD) that uses a powerful magnet and a tiny coil to take detailed pictures inside the milk ducts. The trial enrolls 134 women with pathological nipple discharge to see how well HR-MRD detects lesions that need surgical removal, compared with standard MR ductography.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-resolution magnetic resonance ductography, a non-invasive breast imaging scan
What this could lead to
If it works, women with pathological nipple discharge could avoid invasive surgery just to find the cause, getting answers from a scan instead.
What could go wrong
The scan may miss small lesions or give unclear pictures, and it is still being tested against surgery, so it cannot replace standard checks yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

134 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged between 18 and 75 years old. * Pathological nipple discharge patients who received treatment at Sun Yat-sen Memorial Hospital. The diagnostic criteria for pathological nipple discharge include unilateral, single duct orifice, and spontaneous discharge of serous or bloody fluid. Patients who meet any of the above criteria are considered as pathological discharge. * Willing to sign an informed consent form for clinical research and undergo HR-MRD and MRD examination. Exclusion Criteria: * Patients who have undergone surgery on the nipple-areolar complex of the PND breast side within the past year. * Patients who have claustrophobia or metal implants in their body, which are not suitable for MRI scans. * Patients who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm galactorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Nipple discharge

Contacts and locations

Locations

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.